Global Omics Based Clinical Trials 麻豆原创 Research Report 2024

Publication ID:

PB508241474

Publication Date:

August 27, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Omics is听a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
The global Omics Based Clinical Trials market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Omics Based Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Omics Based Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Omics Based Clinical Trials in Oncology is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Omics Based Clinical Trials include Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer, Covance and Rebus Bio, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Omics Based Clinical Trials, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Omics Based Clinical Trials.
Report Scope
The Omics Based Clinical Trials market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Omics Based Clinical Trials market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Omics Based Clinical Trials companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk
Segment by Type
Interventional Studies
Observational Studies
Expanded Access Studies
Segment by Application
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Omics Based Clinical Trials companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Omics Based Clinical Trials 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Interventional Studies
1.2.3 Observational Studies
1.2.4 Expanded Access Studies
1.3 麻豆原创 by Application
1.3.1 Global Omics Based Clinical Trials 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Respiratory Diseases
1.3.5 Skin Diseases
1.3.6 CNS Diseases
1.3.7 Immunology
1.3.8 Genetic Diseases
1.3.9 Other Indications
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Omics Based Clinical Trials 麻豆原创 Perspective (2019-2030)
2.2 Omics Based Clinical Trials Growth Trends by Region
2.2.1 Global Omics Based Clinical Trials 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Omics Based Clinical Trials Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Omics Based Clinical Trials Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Omics Based Clinical Trials 麻豆原创 Dynamics
2.3.1 Omics Based Clinical Trials Industry Trends
2.3.2 Omics Based Clinical Trials 麻豆原创 Drivers
2.3.3 Omics Based Clinical Trials 麻豆原创 Challenges
2.3.4 Omics Based Clinical Trials 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Omics Based Clinical Trials Players by Revenue
3.1.1 Global Top Omics Based Clinical Trials Players by Revenue (2019-2024)
3.1.2 Global Omics Based Clinical Trials Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Omics Based Clinical Trials 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Omics Based Clinical Trials Revenue
3.4 Global Omics Based Clinical Trials 麻豆原创 Concentration Ratio
3.4.1 Global Omics Based Clinical Trials 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Omics Based Clinical Trials Revenue in 2023
3.5 Omics Based Clinical Trials Key Players Head office and Area Served
3.6 Key Players Omics Based Clinical Trials Product Solution and Service
3.7 Date of Enter into Omics Based Clinical Trials 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Omics Based Clinical Trials Breakdown Data by Type
4.1 Global Omics Based Clinical Trials Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Omics Based Clinical Trials Forecasted 麻豆原创 Size by Type (2025-2030)
5 Omics Based Clinical Trials Breakdown Data by Application
5.1 Global Omics Based Clinical Trials Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Omics Based Clinical Trials Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Omics Based Clinical Trials 麻豆原创 Size (2019-2030)
6.2 North America Omics Based Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Omics Based Clinical Trials 麻豆原创 Size by Country (2019-2024)
6.4 North America Omics Based Clinical Trials 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Omics Based Clinical Trials 麻豆原创 Size (2019-2030)
7.2 Europe Omics Based Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Omics Based Clinical Trials 麻豆原创 Size by Country (2019-2024)
7.4 Europe Omics Based Clinical Trials 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Omics Based Clinical Trials 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Omics Based Clinical Trials 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Omics Based Clinical Trials 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Omics Based Clinical Trials 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Omics Based Clinical Trials 麻豆原创 Size (2019-2030)
9.2 Latin America Omics Based Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Omics Based Clinical Trials 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Omics Based Clinical Trials 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Omics Based Clinical Trials 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Omics Based Clinical Trials 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Omics Based Clinical Trials 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Omics Based Clinical Trials 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Parexel International Corporation
11.1.1 Parexel International Corporation Company Detail
11.1.2 Parexel International Corporation Business Overview
11.1.3 Parexel International Corporation Omics Based Clinical Trials Introduction
11.1.4 Parexel International Corporation Revenue in Omics Based Clinical Trials Business (2019-2024)
11.1.5 Parexel International Corporation Recent Development
11.2 Pharmaceutical Product Development (PPD)
11.2.1 Pharmaceutical Product Development (PPD) Company Detail
11.2.2 Pharmaceutical Product Development (PPD) Business Overview
11.2.3 Pharmaceutical Product Development (PPD) Omics Based Clinical Trials Introduction
11.2.4 Pharmaceutical Product Development (PPD) Revenue in Omics Based Clinical Trials Business (2019-2024)
11.2.5 Pharmaceutical Product Development (PPD) Recent Development
11.3 Charles River Laboratory
11.3.1 Charles River Laboratory Company Detail
11.3.2 Charles River Laboratory Business Overview
11.3.3 Charles River Laboratory Omics Based Clinical Trials Introduction
11.3.4 Charles River Laboratory Revenue in Omics Based Clinical Trials Business (2019-2024)
11.3.5 Charles River Laboratory Recent Development
11.4 ICON plc
11.4.1 ICON plc Company Detail
11.4.2 ICON plc Business Overview
11.4.3 ICON plc Omics Based Clinical Trials Introduction
11.4.4 ICON plc Revenue in Omics Based Clinical Trials Business (2019-2024)
11.4.5 ICON plc Recent Development
11.5 SGS SA
11.5.1 SGS SA Company Detail
11.5.2 SGS SA Business Overview
11.5.3 SGS SA Omics Based Clinical Trials Introduction
11.5.4 SGS SA Revenue in Omics Based Clinical Trials Business (2019-2024)
11.5.5 SGS SA Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Detail
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Omics Based Clinical Trials Introduction
11.6.4 Eli Lilly and Company Revenue in Omics Based Clinical Trials Business (2019-2024)
11.6.5 Eli Lilly and Company Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Omics Based Clinical Trials Introduction
11.7.4 Pfizer Revenue in Omics Based Clinical Trials Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Covance
11.8.1 Covance Company Detail
11.8.2 Covance Business Overview
11.8.3 Covance Omics Based Clinical Trials Introduction
11.8.4 Covance Revenue in Omics Based Clinical Trials Business (2019-2024)
11.8.5 Covance Recent Development
11.9 Rebus Bio
11.9.1 Rebus Bio Company Detail
11.9.2 Rebus Bio Business Overview
11.9.3 Rebus Bio Omics Based Clinical Trials Introduction
11.9.4 Rebus Bio Revenue in Omics Based Clinical Trials Business (2019-2024)
11.9.5 Rebus Bio Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Detail
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Omics Based Clinical Trials Introduction
11.10.4 Novo Nordisk Revenue in Omics Based Clinical Trials Business (2019-2024)
11.10.5 Novo Nordisk Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.